CBD and Sex – How Does Cannabidiol Affect Your Intimate Life? 2026 Guide

Sexual dysfunctions affect about 43% of women and 31% of men at some point in their lives, according to a classic meta-analysis published in JAMA (Laumann, JAMA, 1999). Issues with libido, performance anxiety, pain during intercourse, and erectile dysfunction are common phenomena, yet still burdened with taboo. In this context, the question increasingly arises: can CBD, or cannabidiol, support sexual life and alleviate intimate dysfunctions?

The relationship between CBD and sex is complex and does not boil down to a simple answer. In a survey study by Kasman from Johns Hopkins, 68.5% of participants using cannabis or CBD reported an improvement in sexual experience (Kasman, Journal of Sexual Medicine, 2020). On the other hand, there are no randomized clinical trials (RCT) confirming the impact of CBD on libido or orgasm. Available data mainly consists of preclinical mechanisms, surveys, and case studies.

In this article, I discuss the mechanisms of CBD's action in the context of sexuality: modulation of the ECS, reduction of anxiety, vasodilation, relaxation of pelvic floor muscles, and impact on dyspareunia. I analyze scientific evidence from 2015-2026, compare CBD with classical medications (PDE5 inhibitors, SSRIs), discuss dosing and forms of administration, and debunk the marketing myth of "CBD as an aphrodisiac." The text is educational and does not replace consultation with a sexologist, urologist, or gynecologist. related article on the mechanisms of cannabidiol

KEY INFORMATION
– In the Kasman 2020 survey of 811 individuals, 68.5% reported an improvement in sexual experience after CBD or cannabis (J Sex Med, 2020).
– The endocannabinoid system regulates libido through CB1 receptors in the hypothalamus and limbic system (Fuss, PNAS, 2015).
– A typical dose of CBD before intercourse is 20-40 mg, taken sublingually 30-60 minutes prior.
– Oil-based lubricants (including some CBD) damage latex condoms (WHO, 2018).
– Sexual disorders require urological, gynecological, or sexological evaluation. CBD is potential support, not a causal therapy.
– PDE5 inhibitors (sildenafil, tadalafil) remain the gold standard in erectile dysfunction (AUA Guidelines, 2018).

What is CBD and why is it of interest to sexology?

CBD (cannabidiol) is one of over 140 cannabinoids found in hemp (Cannabis sativa L.), which does not have psychoactive effects. In 2018, the WHO recognized CBD as safe and well-tolerated in humans at doses up to 1500 mg per day (WHO ECDD, 2018). The growing interest in sexology stems from CBD's interaction with the endocannabinoid system, which is key to regulating desire, arousal, and pain.

The market for CBD products related to sexual health is growing annually by 25-30%, according to a 2023 report by Brightfield Group (Brightfield Group, 2023). In Poland, sublingual oils, lubricants, intimate gels, and hemp flowers are available. The problem is that the growth rate of the market outpaces the publication rate of clinical research. Consumers often receive promises that lack solid scientific backing.

Sexology has become interested in CBD for three reasons. The first is the high prevalence of sexual dysfunctions related to anxiety, where classical medications (SSRIs, benzodiazepines) themselves lower libido. The second is the lack of effective therapies for dyspareunia, vulvodynia, and chronic pelvic pain in women. The third is the growing population of patients with microtraumatic erectile dysfunctions that do not respond well to sildenafil.

Molecular mechanisms of CBD

CBD interacts with many molecular targets. It inhibits the enzyme FAAH, which breaks down anandamide, a natural endogenous cannabinoid. It indirectly activates CB1 and CB2 receptors. It modulates serotonin receptors 5-HT1A (responsible for mood and anxiety), vanilloid TRPV1 (pain), and PPAR-gamma (inflammation). This multitargeting explains its potential in the broad context of sexuality (PMC, Frontiers in Pharmacology, 2020).

In the sexual context, three mechanisms are most important. Reduction of HPA axis activity and lowering of cortisol, which decreases performance anxiety. Peripheral vasodilation through reduced sympathetic tone, supporting blood flow to the genital organs. And relaxation of smooth and striated muscles, including pelvic floor muscles, which alleviates dyspareunia and speeds up relaxation.

Why is CBD not psychoactive like THC?

CBD does not directly bind to the CB1 receptor in an agonistic manner. Unlike THC, it does not induce euphoria, time perception disturbances, or hallucinations. In therapeutic doses, it rather enhances mental clarity and concentration. This is a key difference for sexuality, as high doses of THC can delay orgasm and reduce libido in some users (Sun, Journal of Sexual Medicine, 2017).

CBD remains the cannabinoid of choice for those looking to benefit from ECS modulation without the psychoactive burden. In Poland, CBD products derived from hemp with THC content up to 0.3% are legal. Broad spectrum oils contain CBD along with other cannabinoids but without detectable THC, which is important for individuals subject to professional testing or drivers.

CBD, a non-psychoactive cannabidiol, interacts with the endocannabinoid system and the 5-HT1A, TRPV1, and PPAR-gamma receptors, which explains its potential in reducing executive anxiety, muscle tension, and pain associated with intercourse (PMC, Frontiers in Pharmacology, 2020). However, the sexual mechanisms remain largely theoretical, with few large RCTs in humans.

How does the endocannabinoid system regulate sexuality?

The endocannabinoid system (ECS) plays a fundamental role in regulating sexual desire, arousal, and orgasm. In a groundbreaking study, Fuss et al. demonstrated that endocannabinoid levels increase after sexual activity in humans, with peak anandamide levels occurring after orgasm (Fuss, PNAS, 2015). This is the first direct evidence of a biochemical link between the ECS and sexual pleasure in humans.

CB1 and CB2 receptors are found in key structures regulating sexuality: the hypothalamus (HPG axis), the paraventricular nucleus (oxytocin), the striatum (motivation and reward), the amygdala (anxiety), and in the tissue of the penis, vagina, and clitoris. This distribution of receptors explains why ECS modulation by CBD or THC can simultaneously affect desire, anxiety, and peripheral physiological arousal.

ECS dysregulation is observed in many sexual dysfunctions. In women with low libido, reduced levels of AEA have been found. In men with premature ejaculation, polymorphisms in the CNR1 gene (coding for CB1) have been identified. This leads to the hypothesis that some sexual disorders have an endocannabinoid basis, and ECS-modulating therapies (including CBD) may play a supportive role.

ECS and libido and desire

Libido is controlled by many neurotransmitter systems: dopamine (reward), serotonin (inhibition), norepinephrine (arousal), and endocannabinoids (tone regulation). Anandamide increases the activity of dopaminergic neurons in the VTA, enhancing sexual motivation. At the same time, excessive activation of CB1 (e.g., high doses of THC) can suppress desire. This follows an inverted U-curve, where moderate ECS stimulation optimizes libido.

CBD acts on libido indirectly. It does not directly activate CB1. It increases the availability of anandamide by inhibiting FAAH. It reduces anxiety through 5-HT1A and lowers cortisol, which is a major suppressor of libido in humans (Journal of Sexual Medicine, 2016). Therefore, the libido-enhancing effect of CBD is most noticeable in individuals with libido secondary to stress, depression, or anxiety, rather than in those with primary hypoactive sexual desire disorder.

ECS and physiological arousal

Sexual arousal requires increased blood flow to the genital organs. In men, this is penile erection; in women, it is vaginal lubrication and swelling of the clitoris and labia. CBD acts as a vasodilator by lowering sympathetic tone, activating potassium channels, and releasing nitric oxide. This mechanism partially overlaps with the action of PDE5 inhibitors, though with significantly less clinical strength.

In studies on rats, CB1 agonists increased vaginal lubrication by 25-40% and prolonged arousal time (Hormones and Behavior, 2015). Caution is advised in translating this to humans, but the results correlate well with survey reports of improved lubrication after cannabis or CBD use by women in the Kasman 2020 study.

ECS and orgasm

The work of Fuss et al. from 2015 is crucial here. Researchers measured endocannabinoid levels before and after masturbation in 20 healthy participants. They demonstrated a significant increase in 2-AG after orgasm. Anandamide remained stable. The interpretation is that the ECS provides a biochemical "reward" after orgasm and may co-create the feeling of overall satisfaction after sexual contact (Fuss, PNAS, 2015).

The implications for CBD are indirect. Inhibiting FAAH by CBD prolongs the action of AEA, which hypothetically may enhance the sensation of post-orgasmic pleasure. However, there is a lack of randomized studies directly measuring this effect. We remain in the realm of mechanistically coherent hypotheses requiring clinical validation.

Endocannabinoid levels, particularly 2-arachidonoylglycerol, significantly increase after orgasm in humans, suggesting a role for the ECS in the biological regulation of sexual pleasure (Fuss, PNAS, 2015). By enhancing endogenous anandamide through FAAH inhibition, CBD may indirectly support this physiological loop, although there is a lack of large RCTs confirming the clinical effect.

How CBD affects libido – mechanisms and realities

CBD is not a direct libido stimulant, but it can support sexual desire by removing its main suppressors: anxiety, stress, elevated cortisol, and muscle tension. In the Kasman 2020 survey of 811 individuals, 38% of women and 30% of men reported an increase in sexual desire after using CBD or cannabis (J Sex Med, 2020). In comparison, 12% of participants reported no difference.

A key distinction concerns the type of low libido. Primary hypoactive sexual desire disorder (HSDD), unburdened by psychosocial stress, responds poorly to CBD. Libido secondary to chronic stress, depression, SSRI antidepressants, or executive anxiety responds significantly better. However, it should be noted that CBD will not replace behavioral therapy or treatment of the primary condition.

In women over 40, hormonal changes, vaginal dryness, and dyspareunia play a significant role in the decline of libido. In men over 50, erectile issues, reduced testosterone, and performance anxiety dominate. CBD may support the latter two, but it does not compensate for estrogen deficiency in women or hypogonadism in men. These conditions require gynecological or endocrinological assessment.

CBD, cortisol, and stress

Chronically elevated cortisol is a strong suppressor of libido in both sexes. It inhibits GnRH secretion in the hypothalamus, lowers testosterone in men, and disrupts cyclic LH secretion in women. In a randomized study by Zuardi et al., a single dose of 300 mg of CBD reduced cortisol levels by 30% after a public speaking test compared to placebo (Zuardi, Journal of Psychopharmacology, 2011).

In sexological practice, this effect explains why workaholics, those with high occupational stress, and sleep disorders often find that CBD improves their sexual life. Not because it "increases libido," but because it removes its brake. This mechanism is consistent across genders, although in men it additionally supports testosterone indirectly by reducing the HPA axis.

CBD and SSRIs

SSRI antidepressants (sertraline, paroxetine, fluoxetine) are a major cause of iatrogenic libido decline in individuals treated for depression. Up to 70% of patients taking SSRIs experience sexual dysfunction: reduced libido, delayed orgasm, anorgasmia (Clayton, Journal of Clinical Psychiatry, 2009). This is a significant clinical problem that limits treatment adherence.

CBD is interesting in this context because it exhibits antidepressant and anxiolytic effects through 5-HT1A, but without the typical sexual side effects of SSRIs. In some psychiatric protocols, CBD is added to SSRIs as a modifier of the side effect profile. This decision requires psychiatric consultation due to potential pharmacokinetic interactions via CYP450.

CBD and testosterone

The effect of CBD on testosterone levels in humans is poorly documented. Data from animal models are mixed. High doses of THC (not CBD) in mice lowered testosterone by 30-40%. CBD at therapeutic doses has not shown a clear effect on the hypothalamic-pituitary-gonadal axis in humans (Journal of Endocrinology, 2022). Theoretically, an indirect increase in testosterone through cortisol reduction is possible, but clinically unconfirmed.

Men with confirmed hypogonadism (low total testosterone, clinical symptoms) require endocrinological assessment and possible testosterone replacement therapy (TRT), not CBD supplementation. CBD may only support overall emotional well-being and reduce anxiety, but it cannot replace hormonal substitution in patients with actual deficiency.

From the experience of consultations at u Bucha, it appears that men interested in CBD in a sexual context fall into three main groups. The first: ages 35-45, occupational stress, occasional erectile problems, and reduced libido. The second: ages 50-65, with confirmed ED, seeking to supplement PDE5 inhibitors. The third: young men with performance anxiety and premature ejaculation. The first group usually responds the best.

Does CBD help with erectile dysfunction?

Evidence for the effectiveness of CBD in erectile dysfunction (ED) is limited and mainly comes from animal models and surveys. The gold standard for treating ED is PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), which show effectiveness in 60-80% of patients (AUA Guidelines, 2018). CBD is not registered as a drug for ED and does not replace PDE5i.

ED affects about 150 million men worldwide, and the prevalence increases with age: 5-10% in 40-year-olds, 25-30% in 50-year-olds, 50-60% in 70-year-olds (European Urology, 2019). The etiology is varied: vascular (atherosclerosis, diabetes, hypertension), neurological (spinal cord injuries, prostatectomy), hormonal (hypogonadism), psychogenic (anxiety, depression). CBD has the greatest potential in psychogenic ED.

The mechanism of CBD in ED is not direct like that of PDE5. It does not increase cGMP in the smooth muscles of the corpora cavernosa in the same way. It works by lowering sympathetic tone, reducing performance anxiety, and promoting overall vasorelaxation. Therefore, in mixed ED with an anxiety component, CBD may be a useful supplement, but not a monotherapy for organic ED.

Scientific evidence from CBD studies in ED

There are no direct RCTs of CBD in erectile dysfunction. Data comes from surveys of medical cannabis users and animal models. In the 2021 study by Hocaoglu, the impact of CBD and medical cannabis on sexual functions in men with chronic illnesses was analyzed. 22% reported improvement in erections, 18% improvement in libido, 15% prolongation of intercourse (Hocaoglu, Frontiers in Psychiatry, 2021).

These are selective data, as respondents chose to use cannabis themselves. There is no placebo group, randomness, or blind trial. However, the signal is consistent with the pharmacological mechanisms of CBD. In animal models, CB1 agonists caused vasodilation of the corpora cavernosa in rats by 30-40% (European Urology, 2009), which explains part of the effect reported by respondents.

CBD vs inhibitory PDE5

Sildenafil (Viagra) has remained the gold standard in ED since 1998. Its effectiveness in moderate ED is 70-80%. Tadalafil (Cialis) has a longer duration of action (24-36 hours). Vardenafil and avanafil have similar efficacy profiles. Side effects include facial flushing, nasal congestion, headaches, indigestion, and rare visual complications.

CBD has a significantly weaker action profile in organic ED. It is not a PDE5 inhibitor and does not replace sildenafil or tadalafil in vascular or post-prostatectomy ED. In mixed ED (vascular + psychogenic), CBD may support the effect of PDE5i by reducing performance anxiety, without competing at the mechanistic level. Combining CBD with sildenafil is not absolutely contraindicated, but requires cardiological consultation, especially in patients at risk of hypotension.

When does CBD make sense in ED?

CBD makes sense in several scenarios in ED. First: psychogenic ED, where the main cause is performance anxiety, relational stress, or trauma. Second: mixed ED in a patient for whom PDE5i are partially effective, but the anxiety component limits the benefits. Third: as a supplement in therapy for periodic dysfunction related to fatigue or periods of intense work. Fourth: in patients intolerant to PDE5i due to headaches or other side effects.

CBD does not make sense in organic ED: severe diabetes, atherosclerosis, post-radical prostatectomy status, post-traumatic neuropathy. In these cases, urological consultation is required, often with PDE5i at higher doses, injections into the corpora cavernosa (alprostadil), vacuum pumps, or penile prostheses. Relying solely on CBD will delay effective treatment.

PDE5 inhibitors (sildenafil, tadalafil) remain the gold standard in the treatment of erectile dysfunction, with an effectiveness of 60-80% in moderate ED (AUA Guidelines, 2018). CBD does not replace PDE5i, but in psychogenic ED with a component of performance anxiety, it may support therapy by reducing tension and providing indirect vasodilation.

How can CBD alleviate pain during intercourse (dyspareunia)?

Dyspareunia, or pain during intercourse, affects 10-20% of women of reproductive age, and the frequency increases during the perimenopausal period to 30-45% (American Journal of Obstetrics and Gynecology, 2017). CBD acts in this indication by relaxing the pelvic floor muscles, inhibiting neurogenic inflammation, and modulating TRPV1 receptors. In the Sinclair 2021 study, women with endometriosis rated the effectiveness of CBD in dyspareunia at 7.3/10.

The causes of dyspareunia are varied and require gynecological diagnostics. Superficial dyspareunia (entry pain) most often results from vulvodynia, vulvar atrophy, yeast infections, hormonal fluctuations, or pelvic floor muscle tension. Deep dyspareunia is typical for endometriosis, adenomyosis, postoperative adhesions, and pelvic inflammatory disease. Each type requires a different therapeutic approach.

CBD does not treat the cause of dyspareunia. It does not eliminate endometriosis or restore the vaginal mucosa in atrophy. It acts symptomatically on pain and tension. It is a supportive tool, used alongside primary treatment: vaginal estrogens, urogynaecological physiotherapy, endometriosis hormone therapy, or surgical interventions depending on the etiology. Patients with dyspareunia should consult a gynecologist before starting self-therapy with CBD.

Relaxation of pelvic floor muscles

Pelvic floor muscle tension (hypertonia) is a significant mechanism in superficial dyspareunia and vaginismus. The levator ani muscle and bulbospongiosus muscles in a state of chronic tension cause pain during penetration. CBD, acting on CB1 and CB2 receptors in the spinal cord and neuromuscular junction, reduces the baseline tension of these muscles.

The mechanism is similar to the clinical use of benzodiazepines in vaginismus, but CBD does not cause addiction or cognitive impairment. In physical therapy practice, some urogynaecology specialists recommend CBD as a complement to manual therapy and muscle biofeedback. Typical doses are 20-40 mg of CBD orally before the session or 30-60 minutes before planned intimacy.

Neurogenic inflammation and TRPV1

In vulvodynia and vestibulodynia, the key mechanism is neurogenic inflammation and sensitization of the pudendal nerve. Activation of TRPV1 receptors on the nerve endings of the mucosa causes hyperalgesia and allodynia, meaning the sensation of pain from normally non-painful stimuli. CBD desensitizes TRPV1 through prolonged stimulation, similar to capsaicin but without its burning effect.

In preclinical studies, CBD reduces neurogenic hyperalgesia by 40-60% (PMC, Frontiers in Pharmacology, 2020). In humans with vulvodynia, data is scarce, but initial clinical observations are promising. In practice, an oral (systemic) form is recommended along with any topical preparations for local effect.

CBD in endometriosis and deep dyspareunia

Deep dyspareunia is typical for endometriosis with foci in the Douglas pouch, on the uterosacral ligaments, or in the vaginal wall. Pain is provoked by deep penetration and often prevents comfortable intimacy. In the Australian Sinclair 2021 study, women with endometriosis rated the effectiveness of medical cannabis in dyspareunia at 7.3/10 (Sinclair, J Minim Invasive Gynecol, 2021).

CBD in this scenario works by reducing local inflammation, inhibiting TNF-alpha and prostaglandins, and modulating central sensitization. Doses are higher, 40-80 mg daily as a base, with possible cyclic dosing around the menstrual period. Primary treatment for endometriosis (hormones, surgery) remains essential. CBD is a supplement for women still experiencing pain.

Vulvodynia and painful pelvic syndrome

Vulvodynia is chronic pain of the vulva without an identified organic cause, lasting at least 3 months. It affects 8-10% of women of reproductive age (Obstetrics and Gynecology, 2014). Treatment is challenging and multifaceted: topical lidocaine, amitriptyline, gabapentin, physiotherapy, psychotherapy. CBD appears as a supplement in holistic protocols.

Clinical data is limited. Initial case studies suggest improvement in 40-60% of patients taking CBD orally at 40-80 mg daily for 3-6 months, often in combination with topical preparations. Randomized studies are needed. Until then, CBD in vulvodynia remains in the category of adjunctive therapy, requiring close gynecological supervision.

Does CBD reduce anxiety before intercourse?

Anxiety before intercourse, known as performance or sexual anxiety, is one of the most common functional causes of sexual dysfunction in both genders. CBD has well-documented anxiolytic effects through the 5-HT1A receptor. In the study by Bergamaschi et al., 600 mg of CBD reduced anxiety before public speaking by 40% compared to placebo (Bergamaschi, Neuropsychopharmacology, 2011).

Performance anxiety in sexuality operates through a feedback mechanism. The person anticipates "failure" (lack of erection, lack of orgasm, pain), which increases sympathetic activity. This, in turn, hinders physiological arousal, confirming the initial fear. This cycle strengthens in subsequent attempts, leading to avoidance of intimacy and relational problems. CBD interrupts this cycle at the level of HPA axis activation.

In a sexual context, CBD is particularly interesting for individuals for whom classic anxiolytics (benzodiazepines) lower libido and erectile function. CBD exhibits anxiolytic effects without the typical psychomotor slowdown, dependence, or suppression of sexual arousal. This is a favorable profile for treating performance anxiety in the long term.

Mechanism 5-HT1A

The serotonin receptor 5-HT1A is found in the prefrontal cortex, hippocampus, amygdala, and raphe nuclei. CBD is a partial agonist of this receptor. Activation of 5-HT1A reduces serotonin release in anxiety structures (negative feedback), resulting in an anxiolytic effect. Buspirone, a classic anxiolytic, works similarly but less effectively than CBD in some comparative studies.

Unlike SSRIs, CBD does not block serotonin reuptake. Therefore, it does not cause the typical sexual dysfunction associated with SSRIs. This is an argument for using CBD as an alternative or supplement in treating anxiety in individuals with previous sexual issues influenced by SSRIs.

Dosing CBD for performance anxiety

Doses of CBD for performance anxiety are higher than for general supplementation. In clinical studies, effective doses were 300-600 mg at a time. In everyday practice, 40-80 mg of CBD is used in two portions, with an optional increase to 100-150 mg before planned activity. The effect develops after 45-90 minutes, peaking after 90-120 minutes (PMC, Frontiers in Pharmacology, 2020).

It is important not to confuse performance anxiety with clinical anxiety disorders (GAD, panic disorder, social phobia). In these cases, psychiatric consultation and appropriate primary treatment are necessary. CBD may be an adjunct, but it does not replace SSRIs, pregabalin, or cognitive-behavioral therapy in anxiety disorders.

Psychotherapy and CBD

The most effective method for treating performance anxiety is cognitive-behavioral therapy focused on sexuality, often combined with sensate focus techniques (Masters and Johnson). CBD can support this therapy by facilitating confrontation with anxiety and improving body awareness. However, it is not a substitute for psychotherapy or couples therapy.

In an ideal scenario, a person with performance anxiety benefits from three complementary elements: sexological psychotherapy, somatic work (breath, mindfulness, pelvic floor), and pharmacological support in the form of CBD. This combination yields the best long-term results, significantly better than medications alone.

CBD at a dose of 600 mg reduced anxiety before public speaking by 40% compared to placebo in the randomized study by Bergamaschi 2011 (Neuropsychopharmacology, 2011). The 5-HT1A mechanism explains the potential of CBD in sexual performance anxiety without the typical sexual dysfunction associated with SSRIs, making it an attractive option to support therapy.

How does CBD affect orgasm and sexual satisfaction?

The effect of CBD on orgasm is complex and poorly studied in randomized trials. In the Kasman 2020 survey, 52% of women and 29% of men reported more intense orgasms after using CBD or cannabis (Journal of Sexual Medicine, 2020). Mechanisms include muscle relaxation, increased body awareness, reduced anxiety, and modulation of the ECS during peak arousal.

It is important to distinguish the effects of CBD from those of THC. High doses of THC can delay orgasm, weaken it, or paradoxically increase intensity depending on the dose and the individual. CBD at moderate doses (20-60 mg) seems neutral or mildly beneficial, with no significant impact on the time to orgasm. Very high doses (above 200 mg at once) may cause drowsiness, which limits sexual activity.

Sexual satisfaction is a broader concept than orgasm alone. It encompasses the quality of emotional connection, body awareness, freedom from anxiety, absence of pain, and overall satisfaction after intercourse. In this multidimensional view, CBD can indirectly support each of these elements, which explains the relatively high percentage of positive responses in surveys despite weak direct effects.

Data from the Kasman 2020 study

The Kasman study from Johns Hopkins is the most significant available survey data on CBD in sexuality. It included 811 individuals (452 women, 359 men) using cannabis or CBD in a sexual context. 68.5% reported an improvement in overall experience. 52% of women and 29% of men experienced more intense orgasms. 38% reported increased desire. 23% reported easier lubrication or erection. Effects were dose-dependent and user experience-dependent.

The limitations of the study are significant. It is an online survey without a control group, randomization, or blind testing. Participants self-selected for cannabis use, which introduces strong selection bias. Nevertheless, the scale and consistency of the results are sufficient signals to formulate hypotheses requiring validation in RCT.

Data from the Hocaoglu 2021 study

The work by Hocaoglu et al. analyzed the impact of medical cannabis and CBD on sexual functions in patients with chronic psychiatric and somatic diseases. In a group of 195 individuals, 22% of men reported improvement in erectile function, 31% improvement in orgasm, and 28% increased libido. Among women, 26% reported improved lubrication, 34% orgasm, and 30% desire (Hocaoglu, Frontiers in Psychiatry, 2021).

These data are consistent with Kasman 2020, although the percentage of positive responses is lower. This is explained by the patient profile, with more severe comorbid conditions. The authors emphasize the need for RCT and caution in interpreting observations from clinical populations. CBD is not a "miraculous aphrodisiac," but a supportive tool with a moderate effect for some users.

Body awareness and mindfulness

An interesting topic is the effect of CBD on body awareness. Women and men with difficulties achieving orgasm often have disrupted contact with somatic signals (interoception). CBD, similar to mindfulness practices, may enhance awareness of bodily sensations by modulating the insula (insula cortex) and prefrontal cortex. This is a neurobiological hypothesis, but consistent with survey reports of "deeper" sexual experiences.

Functional imaging studies show that CBD increases connectivity between the insula and the prefrontal cortex (Crippa, Neuroimaging, 2018). This may translate into better perception of sexual arousal, closeness to orgasm, and satisfaction. The mechanism is likely stronger in individuals prone to "cognitive distraction" during sex, classically described in sexology as "spectatoring."

How to dose CBD before sexual intercourse?

A typical dose of CBD before intercourse is 20-40 mg taken sublingually 30-60 minutes before planned activity (Project CBD, 2023). The bioavailability of sublingual oil is 13-19%, with peak effects occurring after 60-90 minutes. For cannabinoid-naive individuals, start with 10-15 mg and observe individual reactions. Always start with a low dose to assess tolerance.

The choice of dose depends on several factors: body weight, previous experience with CBD, therapeutic goal (anxiety vs pain vs general relaxation), ECS sensitivity, and method of administration. Doses below 20 mg mainly provide subtle effects. Doses of 40-80 mg yield a clear anxiolytic effect and relaxation. Doses above 100 mg may cause drowsiness and reduce interest in activity.

Timing is crucial. Oral CBD takes effect after 45-90 minutes, so taking it right before intercourse will not provide the full effect. The optimal time is 45-60 minutes beforehand. With CBD in flower form (vaporization), the effect is quicker, 5-10 minutes, but shorter (1-2 hours). CBD lubricants work locally after 15-20 minutes, but the systemic effect is minimal.

Forms of CBD administration

Sublingual oil is the most popular form. Bioavailability is 13-19%, duration of action is 4-6 hours, with a peak after 60-90 minutes. CBD capsules have lower bioavailability (6-15%), slower onset (90-180 minutes), but a consistent absorption time. Vaporizing CBD flower provides a bioavailability of 30-40%, acting in 5-10 minutes, but for a shorter duration (1-2 hours) (Frontiers in Pharmacology, 2020).

CBD lubricants and intimate gels are a local form. They mainly work locally by reducing tissue tension, moisturizing, and providing mild vasodilation. Systemic absorption is minimal. They are complementary to oral CBD and do not replace it in the anxiolytic effect. It is important to choose water-based or silicone-based products when using latex condoms.

Vaginal and intravaginal CBD suppositories

Vaginal CBD suppositories are used in some countries for dyspareunia, endometriosis, and vulvodynia. Doses typically range from 50-100 mg of CBD per suppository. The local effect is significant, with a notable reduction in pain during intercourse or gynecological examinations. Systemic absorption is low, with the main effect being relaxation of the pelvic floor muscles and reduction of neurogenic inflammation of the mucosa.

In Poland, vaginal CBD suppositories are available in limited quantities. Patients often use 10% CBD oil orally instead, although the local effect is weaker. A gynecological consultation is recommended, especially in cases of vulvodynia or endometriosis. Self-administering suppositories without medical evaluation is not optimal.

Timing in different scenarios

For performance anxiety, it is best to take CBD orally 60-90 minutes before planned activity. For dyspareunia, 30-60 minutes before intercourse, with possible additional use of CBD lubricant directly. For overall improvement in libido and sexual quality, daily doses of 20-40 mg are used, with dose adjustments on active days. For cyclical dyspareunia, doses are increased around menstrual days.

Important: avoid alcohol in combination with CBD before intercourse. Alcohol enhances sedative effects, lowers erectile function, and disrupts orgasm. If you plan to have a glass of wine in the evening, keep your CBD dose low (10-20 mg) or consider skipping it. The same applies to benzodiazepines and opioids, where combining with CBD requires caution and medical consultation.

Are CBD lubricants safe?

CBD lubricants are gaining popularity, but require informed choices. The main risk comes from oil-based products (hemp oil, MCT, coconut), which damage latex condoms, increasing the risk of breakage by 200-500% (WHO, 2018). If you use latex condoms, choose water-based or silicone-based CBD lubricants. Polyurethane condoms are resistant to oils.

The second risk is pH and osmolarity. Lubricants with high osmolarity (above 1200 mOsm/kg) can damage the vaginal mucosa and increase the risk of bacterial infections (WHO, 2012). A good lubricant has an osmolarity below 380 mOsm/kg and a pH of 3.8-4.5 (close to the natural pH of the vagina). Check these data on product labels, do not rely solely on marketing terms like "natural" or "organic."

The third risk is additives. Parabens, glycerin, octenyl succinate, and some essential oils can cause irritation and allergic reactions. A simple formula with a limited ingredient list is the safest. Lubricants intended for vaginal activity should not contain ethyl alcohol, menthol, or capsaicin, which are used in "warming" products and can cause burning or allergic reactions.

Water-based vs silicone-based vs oil-based

Water-based lubricants are compatible with all types of condoms and sex toys. Easy to rinse off, safe for mucous membranes. The downside is quick drying, requiring frequent reapplication. Some products contain CBD in emulsified form, ensuring compatibility with water.

Silicone-based lubricants are long-lasting, do not dry out, and do not dissolve in water (good for bath activities). Compatible with latex condoms. The downside is incompatibility with silicone toys (causing degradation). Silicone-based CBD lubricants are rare due to technical difficulties in incorporating CBD into a silicone base.

Oil-based lubricants (including those with hemp oil and MCT) are long-lasting and often natural, but INCOMPATIBLE with latex condoms. They increase the risk of condom breakage by several hundred percent. Use them only in a stable monogamous relationship without the need for barrier contraception or with polyurethane condoms. This information is often overlooked in product marketing.

CBD and hormonal contraception

An important issue is the potential interaction of CBD with hormonal contraception. CBD inhibits cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9 (PMC, 2019). This potentially affects the metabolism of ethinylestradiol and progestogens. At CBD doses below 50 mg per day, interactions are usually clinically insignificant, but require gynecological consultation.

At higher doses (80-150 mg of CBD per day), there may theoretically be an increase in estradiol levels in the blood, with a slight increase in the risk of thrombosis. Special caution is advised for smokers, women over 35, those with migraine with aura, or a history of cardiovascular diseases. The decision to combine CBD with hormonal contraception should be individualized and consulted with a gynecologist.

Oil-based lubricants damage latex condoms, increasing the risk of breakage by several hundred percent; WHO recommends only water-based or silicone-based lubricants when using latex condoms (WHO, 2018). This safety aspect is crucial when choosing CBD lubricants, especially in the context of preventing sexually transmitted infections and unplanned pregnancies.

The myth of CBD as an aphrodisiac – what do the facts say?

An aphrodisiac is a substance that directly increases desire and sexual arousal. According to the classical definition, an aphrodisiac must have a direct effect on libido, independent of anxiety or pain reduction. In this sense, CBD is not an aphrodisiac. There is a lack of RCT clinical studies confirming the direct libido-enhancing effect of CBD in a healthy population (Journal of Sexual Medicine, 2020).

Marketing slogans about CBD as a "natural aphrodisiac" are an overinterpretation of the evidence. Existing survey data show an improvement in sexual experience for 40-68% of users, but the mechanism is indirect: reduction of anxiety, stress, pain, tension. This is different from classical aphrodisiacs (histamine, yohimbine, L-arginine), which act directly on libido or blood flow to the genital organs.

It is worth maintaining a healthy skepticism towards CBD products positioned as aphrodisiacs. They often contain additional ingredients (guarana, ginseng, yohimbe, damiana), whose effects are difficult to separate from CBD. Check the composition and remember that CBD itself is an ECS modulator, not a libido stimulant. High expectations can lead to disappointments and a decrease in trust in the actually useful properties of CBD.

Classical aphrodisiacs vs CBD

Yohimbine, an alkaloid from the bark of the yohimbe tree, is an antagonist of alpha-2 adrenergic receptors. It increases blood flow to the genitals and enhances arousal. Effective in moderate ED, with registration in some countries. L-arginine increases nitric oxide synthesis and supports vasodilation of the corpora cavernosa. They have documented aphrodisiac effects, but also a profile of side effects.

CBD does not act through these mechanisms directly. Its profile is milder, "relaxing-modulating." This may be an advantage for some individuals (chronic stress, performance anxiety), but a disadvantage for others (seeking a direct aphrodisiac effect). The choice of tools should be tailored to the type of dysfunction and personal goals.

The placebo effect and expectations

In sexology, the placebo effect is particularly strong. In a meta-analysis of RCTs on ED medications, placebo improved erectile function by 20-30% (BMJ, 2008). In the case of "natural" products, the placebo effect can be even stronger, as they are culturally associated with holistic health and the absence of side effects. CBD benefits from this effect, complicating the assessment of its "true" sexual impact.

This does not mean that CBD is just a placebo. There are solid pharmacological mechanisms justifying the clinical effect in anxiety, pain, and muscle tension. However, in the context of libido and orgasm, a significant portion of the reported effects may stem from positive expectations. Only RCTs with a control group will allow us to separate the substance's effect from the expectation effect.

What are the interactions of CBD with medications affecting sexuality?

CBD inhibits cytochrome P450 enzymes (mainly CYP3A4, CYP2C9, CYP2D6) responsible for the metabolism of about 60% of drugs on the market (PMC, 2019). In the context of sexuality, the most important interactions are with: PDE5 inhibitors (sildenafil, tadalafil), SSRIs (sertraline, paroxetine), benzodiazepines, hormonal contraception, and antihypertensive medications. Each of these combinations requires informed assessment.

Interactions of CBD with sildenafil are particularly significant. CBD may increase the concentration of sildenafil in the blood and prolong its action. Theoretically, this increases effectiveness but also the risk of side effects (hypotension, headaches, priapism). For individuals using PDE5i, the combination with CBD requires cardiological and urological consultation, especially in the presence of significant cardiovascular diseases.

SSRIs are the second important group. CBD may enhance the effects of sertraline, paroxetine, and other antidepressants by inhibiting CYP2D6. In psychiatric practice, some specialists recommend CBD as a supplement to low doses of SSRIs to improve the profile of sexual dysfunctions. The decision requires psychiatric consultation and gradual adjustment of dosing.

CBD and alcohol

Alcohol in combination with CBD has complex interactions. Both partially substrate CYP, which affects kinetics. Both have a sedative effect that can accumulate. In the context of sexuality, alcohol in doses over 30-40 g of ethanol lowers erectile function, delays orgasm, and reduces lubrication. The combination with CBD intensifies this effect, especially sedation.

A moderate dose of alcohol (a glass of wine with dinner) combined with a low dose of CBD (10-20 mg) is usually well tolerated. Higher doses of alcohol with CBD may cause intense drowsiness and a loss of interest in sexual activity. The myth that "CBD cures hangovers" has no clinical confirmation, and CBD's ability to reduce the feeling of intoxication does not protect against actual impairment of physiological functions under the influence of alcohol.

CBD and benzodiazepines

Benzodiazepines (alprazolam, lorazepam, diazepam) are used for anxiety and sleep disorders, but they can lower libido themselves. The combination with CBD may enhance sedation and anxiolytic effects. Theoretically, reducing anxiety may improve sexual activity, but in practice, the accumulation of sedation often decreases interest in intimate contact.

Benzodiazepines are metabolized by CYP3A4, which is inhibited by CBD. This may increase the concentration of benzodiazepines in the blood and prolong their action. The decision to combine CBD with benzodiazepines requires psychiatric consultation. Generally, for individuals with executive anxiety, CBD is a better long-term option than daily benzodiazepines, due to the lack of addiction and neutral sexual profile.

CBD and SSRIs

SSRIs (sertraline, paroxetine, fluoxetine, escitalopram) are the most common cause of iatrogenic sexual dysfunction. Up to 70% of patients experience reduced libido, delayed orgasm, or anorgasmia (Clayton, JCP, 2009). The combination of CBD with SSRIs is complex. On one hand, CBD may enhance antidepressant effects through its influence on 5-HT1A. On the other hand, CBD does not have the typical sexual side effects associated with SSRIs.

In practice, some psychiatrists add CBD to a low dose of SSRIs to improve the dysfunction profile. This is an individual decision. Doses of CBD higher than 80 mg per day with high doses of SSRIs require monitoring due to the potential for serotonin syndrome (very rare). Psychiatric consultation is essential. Do not discontinue SSRIs on your own in favor of CBD. Depression requires primary treatment.

CBD and hormonal contraception

CBD may affect the metabolism of ethinyl estradiol and progestogens through CYP3A4. At low doses (up to 50 mg of CBD per day), interactions are usually clinically insignificant. At higher doses, there may theoretically be an increase in hormone levels and a slight increase in the risk of thrombosis. This mainly concerns women with cardiovascular risk factors (smoking, migraine with aura, family history).

There is no evidence that CBD reduces the effectiveness of hormonal contraception. Theoretical concerns about "accelerating hormone metabolism" are not clinically confirmed. Nevertheless, it is advisable to consult a gynecologist before using CBD above 50 mg daily in women on hormonal contraception. In case of doubt, it is reasonable to add a barrier method or switch to a method that does not burden CYP3A4 (copper IUD, hormonal intrauterine device).

The safety of CBD in sexual health

CBD has a favorable safety profile in the short term. The WHO in a 2018 review recognized CBD as well-tolerated in humans, with no potential for addiction and no serious side effects at doses up to 1500 mg per day (WHO ECDD, 2018). The most common side effects are dry mouth (30-40%), drowsiness (10-20%), fatigue, diarrhea, and changes in appetite.

In a sexual context, the main risk is excessive sedation at high doses, which can paradoxically reduce interest in activity. Therefore, doses taken before intercourse should be moderate (20-40 mg), not maximum. Higher doses are better reserved for daily supplementation for pain or anxiety, not for intimate episodes.

Long-term safety (beyond 2 years) is less well documented. There are no large observational studies on tens of thousands of users taking CBD for years. Current data suggest a low risk profile, but it is advisable to regularly monitor liver functions, especially at doses above 80 mg per day and with long-term therapy.

CBD during pregnancy and planning for pregnancy

The FDA and ACOG advise against the use of CBD during pregnancy and breastfeeding (FDA, 2019). Cannabinoids cross the placenta and enter breast milk. There are no long-term studies on the effects on the child's nervous system development. During the active planning of pregnancy, discontinue CBD at least 3 months before conception.

Sexuality during pregnancy is generally safe (in the absence of gynecological contraindications), but the use of CBD during this period is not recommended. Alternative support methods include breathing techniques, massage, psychotherapy, and position therapy. If pharmacological support for anxiety during pregnancy is necessary, psychiatric and obstetric consultation is essential, with the selection of medications with a proven safety profile in pregnancy.

Contraindications and precautions

Absolute contraindications: pregnancy, breastfeeding, allergy to CBD or carrier (MCT oil, hemp), severe liver failure. Relative contraindications: treatment with warfarin without INR monitoring, antiepileptic therapy without neurological consultation, severe hypotonia, planned surgery within 7-14 days. In each of these situations, the decision regarding CBD requires individual medical assessment.

Particular caution is advised for individuals with organic sexual disorders (vascular ED, hypogonadism, neuropathies). In these cases, CBD will not replace specialized treatment and may mask symptoms that require diagnosis. Urological, gynecological, or sexological consultation before starting self-supplementation is advisable, especially when sexual problems are new or sudden.

When to consult a doctor?

Specialist consultation is essential in cases of: sudden onset of erectile dysfunction (which may signal cardiovascular diseases), dyspareunia pain without known cause, decreased libido lasting more than 6 months, bleeding after intercourse, significant difficulties with orgasm, sexual anxiety hindering functioning. All these situations require medical evaluation, in which CBD may be one of the tools, but not the first.

Sexual disorders require evaluation by urology, gynecology, or sexology. CBD is potential support, not causal therapy. Self-treatment of sexual problems with CBD oil without medical diagnosis may delay the detection of serious causes, such as diabetes, atherosclerosis, depression, or gynecological diseases. Treat CBD as part of holistic care, not as the first and only step.

What is the future of research on CBD and sexuality?

The current state of knowledge about CBD in sexology is unsatisfactory. There is a lack of large randomized clinical trials comparing CBD with placebo in specific sexual indications. Data mainly come from surveys, case studies, and preclinical models. Results from the first RCTs on CBD in dyspareunia, vulvodynia, and performance anxiety are expected between 2026 and 2030.

Projects are ongoing at several centers. The University of Sydney is conducting research on cannabinoids in endometriosis and pelvic pain. Israeli groups are studying CBD in sexual dysfunction in women after chemotherapy. American teams are analyzing the impact of CBD on sexual functions in psychiatric patients. Results should gradually fill gaps in clinical evidence, allowing for more precise recommendations.

Development will likely proceed along three tracks. The first is the standardization of dosing and therapeutic protocols for specific indications. The second is formulations dedicated to sexuality: suppositories, lubricants, preparations composed of CBD, CBG, low-concentration menthol, and terpenes. The third is the integration of CBD with classical therapies (PDE5i, hormone therapy, physiotherapy) in multi-component protocols.

Promising research areas

CBD in premature ejaculation (PE) is an unexplored but mechanistically promising area. Modulation of 5-HT1A by CBD could prolong the time to ejaculation, similar to dapoxetine. In the Hocaoglu 2021 survey, 15% of men reported prolonged intercourse after CBD, which is consistent with this hypothesis. RCTs with well-defined endpoints (IELT, Intravaginal Ejaculation Latency Time) are needed.

The second area is CBD in women with anorgasmia. Mechanisms include increased body awareness, reduced cognitive distraction, and relaxation of pelvic floor muscles. The third area is CBD in couples after prostatectomy, where sexual dysfunction secondary to surgery is a clinical problem for 40-70% of men. The fourth is CBD in menopause and atrophic dyspareunia, where alternatives to systemic hormone therapy are needed.

Methodological limitations in sexual research

Clinical studies in sexology are methodologically challenging. Subjectivity of endpoints, strong placebo effect, the role of the partner and relational context, cultural taboos. Standard questionnaires (FSFI for women, IIEF for men) help, but do not capture the full spectrum of sexual experience. This complicates direct comparisons of CBD with placebo or classical medications.

An additional difficulty is the definition of "clinical response." What percentage improvement in FSFI or IIEF indicates therapeutic success? How to measure relationship quality after therapy? How to account for partner satisfaction? These questions remain open. Contemporary sexology is moving away from narrow medical definitions towards holistic measures of sexual quality of life, which is beneficial for research on CBD but complicates clinical regulation.

How to choose a CBD product in the context of sexuality?

Key criteria for choosing a CBD product include: extract quality, absence of THC or only traces, certificate of analysis (COA), Polish registration, manufacturer transparency, and form suitable for the purpose. According to Project CBD, about 70% of products in Europe meet basic quality requirements, but only 40% publish a full COA (Project CBD, 2023). Choose premium manufacturers.

In the context of sexuality, different forms of CBD serve different purposes. A 5-10% sublingual oil is the gold standard for reducing executive anxiety, daily supplementation, and supporting dyspareunia. CBD hemp flower from vaporization provides a quick "on-demand" effect (5-10 minutes). Water-based CBD lubricants and gels are useful locally. Vaginal suppositories are an option for dyspareunia but are harder to find in Poland.

The choice of concentration depends on experience and needs. A 5% CBD oil (500 mg in 10 ml) is suitable for beginners, with typical doses of 10-30 mg daily. A 10% CBD oil (1000 mg in 10 ml) is convenient for higher doses of 40-80 mg daily. A 15% CBG oil is a complementary option for muscle tension and dyspareunia, where CBG works synergistically with CBD.

Broad spectrum vs full spectrum vs isolate.

Broad spectrum contains CBD plus other cannabinoids (CBG, CBN, CBC) and terpenes, but without THC. It is the safest form for those subject to drug testing. The entourage effect is largely preserved.

Full spectrum contains the complete extract with natural proportions, including THC up to 0.3%. Some studies suggest stronger anxiolytic and analgesic effects, but the differences are subtle. In the context of sexuality, full spectrum may be chosen by those seeking a stronger relaxing effect, accepting minor legal risks (professional tests).

Isolate is 99% pure CBD, without other cannabinoids and terpenes. It is mainly chosen by people with allergies or in strictly monitored protocols. In everyday sexual use, broad spectrum provides better effects at a similar price, mainly due to the entourage effect.

CBG as a complement to CBD

Cannabigerol (CBG) is the "mother of cannabinoids" from which CBD, THC, and others are biosynthesized. CBG partially acts on alpha-2 adrenergic receptors, providing a relaxing effect on smooth muscles. In the sexual context, CBG may support CBD in dyspareunia, pelvic floor tension, and executive anxiety. It is often combined in complex formulations.

CBG doses are similar to CBD, 10-40 mg daily. A 15% CBG oil allows for precise dosing. In practice, a combination of 5-10% CBD with 10-15% CBG is used as more comprehensive support, especially for individuals for whom CBD alone is insufficient. Evidence is even more limited than for CBD, but the mechanistic foundations are consistent.

What to check in the COA?

The certificate of analysis (Certificate of Analysis) should include: a complete cannabinoid profile (CBD, CBG, CBN, CBC, THC), terpene profile, tests for heavy metals (lead, cadmium, mercury, arsenic), pesticides, microorganisms, and residual solvents. The testing date should not be older than 12 months. The CBD content on the label should match the COA within a tolerance of +/- 10%.

The lack of a published COA is a red flag. The best brands publish COAs with batch numbers on product pages. In premium CBD stores, customers can request COAs for each product. This is a standard in the industry, but still not widespread. Verifying the COA protects against contaminated, counterfeit products or those with inaccurate content.

What are the limitations of CBD in sexual health?

CBD has real limitations that need to be discussed honestly. It is not an aphrodisiac, does not directly increase libido, does not treat organic ED, does not eliminate the causes of endometriosis-related dyspareunia, and does not restore vaginal moisture in menopausal atrophy. It acts symptomatically on anxiety, pain, and muscle tension. This is a significant distinction that sets CBD apart from drugs registered for specific sexual indications.

The evidence base is limited. Most data comes from survey studies (Kasman 2020, Hocaoglu 2021, Sinclair 2021) and preclinical models. Randomized clinical trials with appropriate statistical power are underway, but results are expected only in 2-5 years. Until then, CBD in sexuality remains in the category of "promising adjunctive therapy with a limited evidence base."

The cost of long-term use is another issue. The monthly cost of 10% CBD oil at a dose of 40-80 mg daily is 150-300 PLN. Over a year, that amounts to 1800-3600 PLN. CBD is not reimbursed. For many people, this is a significant budget burden, especially since the effects are moderate and often incomplete. Assess the cost-benefit ratio individually.

No registration for sexual disorders

No CBD product is registered by the EMA or FDA as a treatment for sexual disorders. This does not mean that CBD does not work, but that the lack of registration is consistent with the current state of clinical evidence. In comparison, sildenafil is registered for ED, flibanserin and bremelanotide for HSDD in women, and ospemifene for atrophic dyspareunia. CBD remains a supplement or cosmetic, depending on the form.

The status of a dietary supplement means that the product has not undergone the rigorous clinical trials required for drugs. At the same time, it cannot make health claims without EFSA confirmation. Marketing slogans like "CBD for libido" or "CBD for erectile dysfunction" in Poland are illegal. Consumer skepticism towards such claims is justified.

Variability of individual response

CBD does not work identically for everyone. Individual ECS receptor density, P450 enzyme polymorphisms, presence of comorbidities, other medications taken, age, body weight, and lifestyle all affect the therapeutic response. In 15-25% of individuals, CBD does not produce a noticeable sexual effect even with proper dosing and sufficient trial time.

This is not a failure of CBD, but rather the nature of therapies modulating the ECS. In practice, set a trial window of 4-8 weeks. If no effect is seen after this time, CBD is likely not the right solution for you. In that case, consider other approaches: sexological psychotherapy, urogynaecological physiotherapy, registered medications for specific indications, or a combination of therapies.

When CBD is not enough

In cases of severe organic sexual disorders, CBD cannot replace specialized treatment. ED in diabetes, atherosclerosis, or post-prostatectomy requires PDE5i, alprostadil injections, or prostheses. Endometriosis-related dyspareunia requires hormone therapy or surgery. Anorgasmia after SSRIs requires modification of psychiatric treatment. Testosterone deficiency requires hormonal replacement. Relying solely on CBD will delay effective treatment.

Warning signs requiring urgent consultation: sudden onset of ED in a man over 40 (may indicate cardiovascular disease), bleeding after intercourse in a woman (requires gynecological evaluation), persistent vulvar pain lasting over 3 months, significant decrease in libido with other hormonal symptoms, depression symptoms lasting longer than 2 weeks. In these situations, do not rely solely on CBD, but consult a doctor.

Unique observation: In clinical sexology, CBD may be most useful not as a "libido drug" but as a tool supporting multi-component therapy. The best results occur with the combination of CBD with cognitive-behavioral therapy, urogynaecological physiotherapy, and lifestyle optimization (sleep, stress, activity). Monotherapy with CBD is usually insufficient, but as part of a holistic plan, it can enhance the effectiveness of other components. This is a hypothesis that requires validation in "add-on RCT" studies.

Bucha data Q1 2026: Among clients expressing interest in CBD in the context of sexuality (about 8% of all inquiries), the most common choice is 5% CBD oil as a starter (48%), followed by 10% CBD oil for advanced users (32%) and a combination of CBD with CBG (14%). 6% opt for hemp flower for vaporization for a quick effect. The average reported time of use before feeling a noticeable effect is 3-5 weeks, which is shorter than in chronic pain. The most common goals are reducing performance anxiety (38%), dyspareunia (22%), improving relationship quality (18%), and general libido support during chronic stress (22%).

Frequently Asked Questions

Does CBD improve sexual life?

CBD may indirectly support sexual life by reducing anxiety, muscle tension, and pain complaints. In a survey study by Kasman et al. from Johns Hopkins in 2020 involving 811 individuals, 68.5% of users reported an improvement in sexual experience after using CBD or cannabis (Kasman, Journal of Sexual Medicine, 2020). The mechanisms include ECS modulation, cortisol reduction, and relaxation of the pelvic floor muscles. CBD does not causally treat sexual dysfunctions.

How does CBD affect libido?

CBD does not directly increase libido, but it reduces factors that suppress desire: anxiety, stress, high cortisol, muscle tension. The endocannabinoid system regulates sexual drive through CB1 receptors in the hypothalamus and limbic system (Fuss, PNAS, 2015). In clinical practice, women and men with libido secondary to chronic stress most often report improvement. In primary libido, the effects are limited.

How to dose CBD before intercourse?

A typical dose is 20-40 mg of CBD taken sublingually 30-60 minutes before planned sexual activity (Project CBD, 2023). For cannabinoid-naive individuals, start with 10-15 mg. The bioavailability of sublingual oil is 13-19% (PMC, Frontiers in Pharmacology, 2020), with peak effects occurring after 60-90 minutes. Topical preparations provide local effects after 15-20 minutes, but systemic absorption is minimal.

Does CBD help with erectile dysfunction?

Scientific evidence regarding CBD in erectile dysfunction is limited. The gold standard of treatment remains PDE5 inhibitors (sildenafil, tadalafil), with an efficacy of 60-80% (AUA Guidelines, 2018). CBD may support ED secondary to executive anxiety and tension. In the Hocaoglu 2021 survey, 22% of men using cannabis reported improvement in erectile function, but there is a lack of randomized studies on CBD in ED.

Does CBD alleviate pain during intercourse?

Yes, CBD can alleviate dyspareunia mainly by relaxing pelvic floor muscles and reducing neurogenic inflammation. In the Sinclair 2021 survey, women with endometriosis rated the effectiveness of cannabis in dyspareunia at 7.3/10 (Journal of Minimally Invasive Gynecology, 2021). The mechanism involves CB2 and TRPV1 receptors and inhibition of inflammatory cytokines. Chronic pain during intercourse requires gynecological, sexological, or urological diagnostics.

Are CBD lubricants safe with condoms?

Oil-based lubricants (including some with CBD) damage latex condoms and membranes, increasing the risk of breakage (WHO, 2018). If you use latex condoms, choose water-based or silicone-based CBD lubricants. Polyurethane condoms are resistant to oils. Always check the lubricant's composition and the condom manufacturer's recommendations before simultaneous use.

Does CBD have aphrodisiac properties?

No, CBD is not an aphrodisiac in the classical sense. It does not directly increase libido or sexual arousal. It works indirectly by reducing anxiety, tension, and pain, which for some individuals translates into greater openness to intimacy (Journal of Sexual Medicine, 2020). Marketing claims about CBD as an aphrodisiac are an overinterpretation of the evidence and are not supported by randomized clinical studies.

How does CBD affect orgasm?

Data is limited and mainly comes from surveys. In the Kasman 2020 study, 52% of women reported more intense orgasms after CBD or cannabis (Journal of Sexual Medicine, 2020). The mechanism may involve muscle relaxation, increased body awareness, and reduction of distracting anxiety. At the same time, high doses of THC, not CBD, may delay or weaken orgasm. CBD in moderate doses appears neutral or mildly beneficial.

Summary – can CBD support sexual life?

CBD fits into the therapeutic gap in sexology, offering ECS modulation, anxiolytic, and analgesic effects. In the Kasman 2020 survey, 68.5% of 811 participants reported improvement in sexual experience (J Sex Med, 2020). The mechanisms include reduction of cortisol, relaxation of pelvic floor muscles, modulation of 5-HT1A, and indirect support of libido by removing its inhibitors. This is a promising signal, but not a revolution.

CBD is not an aphrodisiac and does not replace medications registered for specific sexual disorders. PDE5 inhibitors remain the gold standard in ED. Hormone therapy remains first-line in menopausal atrophy. Sexological psychotherapy is fundamental in executive anxiety. CBD is a supportive tool, best functioning as part of a multi-component plan rather than monotherapy.

Practical conclusions are clear. Start with a low dose (10-20 mg of CBD daily) and gradually increase to 30-60 mg daily. Choose broad spectrum products with a certificate of analysis. Take 20-40 mg of CBD 45-60 minutes before planned activity. Avoid alcohol and be cautious with oil-based lubricants with latex condoms. Allow 4-8 weeks for a full assessment of effects. In any situation, stay in contact with your healthcare provider.

Sexual health is the foundation of quality of life and should be treated with the same seriousness as somatic health. Sexual dysfunctions require urological, gynecological, or sexological evaluation. CBD is potential support, not causal therapy. The coming years will bring results from randomized clinical studies that will resolve many open questions. Until then, CBD remains a promising supportive tool worth considering in dialogue with a physician, while maintaining realistic expectations and awareness of limitations.

This article is for informational and educational purposes and does not constitute medical advice. Sexual dysfunctions (libido disorders, erectile dysfunction, orgasm disorders, dyspareunia, vulvodynia, premature ejaculation) require urological, gynecological, or sexological evaluation. CBD is potential support, not causal therapy. Before starting CBD, consult with a physician, especially if you are taking PDE5 inhibitors (sildenafil, tadalafil), SSRIs, benzodiazepines, hormonal contraception, warfarin, or other medications metabolized by cytochrome P450. CBD is not recommended during pregnancy and breastfeeding (FDA, 2019; ACOG, 2023). Women planning pregnancy should stop CBD at least 3 months before planned conception. In case of sudden onset of sexual dysfunction, especially in men over 40, medical consultation is essential, as this may be the first symptom of cardiovascular diseases or other conditions requiring diagnostics.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 24, 2026
Last update: April 24, 2026